Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls

Tu, Kun-Yu; Wu, Ming‐Kung; Chen, Yen‐Wen; Lin, Pao‐Yen; Wang, Hung-Yu; Wu, Ching-Kuan; Tseng, Ping‐Tao

doi:10.1097/md.0000000000002411

Cited by 40 publications

(44 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between VEGF and treatment response is unclear; a recent study found no relationship between either serum VEGF or BDNF with response or depression severity, despite decreases alongside antidepressant treatment 81. Insulin-like growth factor-1 is an additional factor with neurogenic functions that may be increased in depression, reflecting an imbalance in neurotrophic processes 82,83. Basic fibroblast growth factor (or FGF-2) is a member of the fibroblast growth factor family and appears higher in depressed than control groups 84.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers for depression: recent insights, current challenges and future prospects

Strawbridge¹,

Young²,

Cleare³

2017

NDT

306

156

View full text Add to dashboard Cite

A plethora of research has implicated hundreds of putative biomarkers for depression, but has not yet fully elucidated their roles in depressive illness or established what is abnormal in which patients and how biologic information can be used to enhance diagnosis, treatment and prognosis. This lack of progress is partially due to the nature and heterogeneity of depression, in conjunction with methodological heterogeneity within the research literature and the large array of biomarkers with potential, the expression of which often varies according to many factors. We review the available literature, which indicates that markers involved in inflammatory, neurotrophic and metabolic processes, as well as neurotransmitter and neuroendocrine system components, represent highly promising candidates. These may be measured through genetic and epigenetic, transcriptomic and proteomic, metabolomic and neuroimaging assessments. The use of novel approaches and systematic research programs is now required to determine whether, and which, biomarkers can be used to predict response to treatment, stratify patients to specific treatments and develop targets for new interventions. We conclude that there is much promise for reducing the burden of depression through further developing and expanding these research avenues.

show abstract

Section: Introductionmentioning

confidence: 99%

Biomarkers for depression: recent insights, current challenges and future prospects

Strawbridge¹,

Young²,

Cleare³

2017

NDT

306

156

View full text Add to dashboard Cite

show abstract

“…In human acromegaly patients, recent studies have reported cognition deficits, decreased short-term and long-term memory, anxiety and impaired decision making, and decreased activities in pre-frontal and mid-temporal cortices in brain (274,275,276,277). Interestingly, recent reports and multiple meta-analyses directly implicate a higher than normal serum IGF-1 as a disease trait marker in major depressive disorder (MDD) and bipolar disorder (BD) further stimulating the pleiotropy of GH action in cognitive development and maintenance (278,279,280,281).…”

Section: Cognitive Studies In Humans With Ghr Deficiencymentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?

Basu

Qian

Kopchick

2018

European Journal of Endocrinology

View full text Add to dashboard Cite

Growth hormone (GH) is produced primarily by anterior pituitary somatotroph cells. Numerous acute human (h) GH treatment and long-term follow-up studies and extensive use of animal models of GH action have shaped the body of GH research over the past 40-50 years. Work on the GH receptor (R) knock-out (GHRKO) mice and results of studies on GH resistant Laron Syndrome (LS) patients have helped define many physiological actions of GH including those dealing with metabolism, obesity, cancer, diabetes, cognition, and aging/longevity. In this review, we have discussed several issues dealing with these biological effects of GH and attempt to answer the question of whether decreased GH action may be beneficial.

show abstract

“…In addition, IGF-1 can mediate antidepressant effect in MDD patients and its levels in the cerebrospinal fluid have been found to vary with antidepressant treatment (11). Currently, several studies have provided evidence about higher serum IGF-1 levels in MDD or bipolar disorder patients than in controls (11)(12)(13)(14). More than 90% of the circulating IGF-1 is bound to IGFBP-3, which regulates the biological activity and availability of IGF-1.…”

Section: Insulin-like Growth Factor Binding Protein-3mentioning

confidence: 99%

Association of EGF, IGFBP-3 and TP53 Gene Polymorphisms with Major Depressive Disorder in Slovak Population

Mahmood

Evinová

Škereňová

et al. 2016

Cent Eur J Public Health

View full text Add to dashboard Cite

SUMMARYBackground: Major depressive disorder (MDD) is a main public health concern worldwide. Despite extensive investigations, the exact mechanisms responsible for MDD have not been identified. Epidermal growth factor (EGF) and insulin growth factor binding protein-3 (IGFBP-3) are involved in brain function. Tumour suppressor protein p53 is widely involved in neuronal death in response to different forms of acute insults and neurological disorders. The present study focuses on the possible associations of the single-nucleotide polymorphisms (SNP) of EGF A61G (rs4444903), IGFBP-3 C32G (rs2854746) and TP53 G72C (rs1042522) genes with MDD risk in the Slovak population.Methods: The present case-control association study was carried out in 111 confirmed MDD patients and 207 healthy subjects. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism methods.Results: Logistic regression analysis showed no association between SNPs of selected genes and MDD risk in the Slovak population. However, the stratification of individuals by gender revealed that males carrying IGFBP-3 G alleles (G32G or GG) had marginally increased risk for developing MDD as compared to CC homozygous males (p = 0.09). In women, inverse association was observed between SNP rs1042522 and MDD risk (p = 0.04 for recessive model).Conclusion: Our results suggest the protective effect of minor allele 72C of TP53 gene towards MDD. The disruption of mechanisms involved in cell survival and death regulation may be involved in pathophysiology of MDD.

show abstract

Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls

Abstract: Supplemental Digital Content is available in the text

Cited by 40 publications

References 56 publications

Biomarkers for depression: recent insights, current challenges and future prospects

Biomarkers for depression: recent insights, current challenges and future prospects

MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?

Association of EGF, IGFBP-3 and TP53 Gene Polymorphisms with Major Depressive Disorder in Slovak Population

Contact Info

Product

Resources

About